Pope @Janetbirdope et al. Parenteral (IM and/or IA) superior to oral steroids in early RA. Better discontinuation of steroids with no difference in need for advanced therapies. @RheumNow #ACR25 Abstr#1355 #ACRbest https://t.co/OyvnzEGlLE

• https://x.com/RichardPAConway/status/1982845746950164581/photo/1

In a prespecified exploratory analysis of REGENCY trial data by DrRovin et al, Bet. wks 24 and 76: Obinutuzumab ⬇️ LN flares vs. PBO (HR 0.44; p=0.0074) Pts on Obi had less unfavorable kidney outcomes vs. PBO (HR 0.37; p=0.0039) Addtl tx option for LN #ACR25 @RheumNow Abs1521 https://t.co/N5K9Nzh71E

• https://x.com/RHEUMarampa/status/1982844740291952655/photo/1

Simko et al. 6-monthly vs 3-monthly MTX lab monitoring. 3821 patients. Appears to be no difference. Potential for significant cost-savings and reduced burden to patients. @RheumNow #ACR25 Abstr#1370 #ACRbest https://t.co/G3tNQq8qXT

• https://x.com/RichardPAConway/status/1982844488977437109/photo/1

I wouldn't sleep on this. 😴💤 Abstract 1413: In a PsA cohort, restless leg syndrome was linked to: 🔹 ↑ disease activity (polyarthritis, swollen joints, DAPSA) 🔹 Worse physical function (↑ HAQ) 🔹 Fatigue, anxiety, depression, & poorer sleep quality @RheumNow #ACR25

Post-hoc analysis of CARE(Ph2B) Study to assess sustained responses in mSLEDAI-2K vs. PBO x 12mos in pts given Cenerimod Sustained response in Cenerimod Ex-4mg (63.5%) > PBO (50%); HR 1.43 Ongoing research, further data needed. #ACR25 @RheumNow Abs1519 https://t.co/cQbVVIIyxW

• https://x.com/RHEUMarampa/status/1982843734011105721/photo/1

Really useful observational study, 305 pts with TAK Out of 205 pts w/subsequent imaging, 72 (35%) w/NEW lesions in previously-unaffected territory Majority of lesions stenotic. Emphasizes importance of regular monitoring #ACR25 @RheumNow Abstr#1631 https://t.co/zoWjH0lEym

• https://x.com/EBRheum/status/1982843733952385436/photo/1
• https://x.com/EBRheum/status/1982843733952385436/photo/1

Infection data from SELECT-GCA: Glucocorticoids seem to drive overall infectious risk UPA use associated with higher zoster - vaccinate!! @RheumNow #ACR25 Abst# 0895 https://t.co/ueVbFPxG0Q

• https://x.com/Dr_Brian_MD/status/1982843521112641587/photo/1

Who with #SSc-ILD will progress? progression is non linear - can stabilize and worsen Search for Predictive biomarker For clinical care & enriching RCTs Maybe #KL6 🤷‍♀️ Maybe IP-10, MIG No strong #biomarker Depends on what is used #ACR25 @RheumNow @ACRheum Abst#0882 #0883 https://t.co/lyTRUEY9SI

• https://x.com/Janetbirdope/status/1982843159433625722/photo/1
• https://x.com/Janetbirdope/status/1982843159433625722/photo/1
• https://x.com/Janetbirdope/status/1982843159433625722/photo/1

After At-risk RA, time to discuss At-risk PsA patients ARP-PsA Prospective cohort 1400+ pts 8.4% met ARP-PsA criteria (arthralgia + Fam Hx +Pso, not referred via Dermatology) Risk factors: Pso >15 years Pso + Family Hx US synovitis/enthesitis At 1 yr follow-up 30% progressed https://t.co/ZY2ezh8nZN

• https://x.com/AurelieRheumo/status/1982842237986787364/photo/1
• https://x.com/AurelieRheumo/status/1982842237986787364/photo/1

Prednisone remains both lifeline and liability. New PRED-SAFE SDM tool helps patients and clinicians navigate that tension—visualizing benefits and harms to guide tapering. In pilot testing, 93% had no residual decisional conflict. @RheumNow #ACR25 Abstract#1052 #ACRbest https://t.co/CgQ75N7A1p

• https://x.com/JihaRheum/status/1982842223743164901/photo/1

Abstract 1431: Radiographic sacroiliitis in #PsA: insights from an Indian cohort - Cervical and lumbosacral spine syndesmophytes were common - Levels C5, C6, and L4 vertebrae frequently involved including syndesmophyte damage w/ non-marginal bridging @RheumNow #ACR25

Picture this 👉radiographic joint damage tied to worse physical function in #PsA: 🔹 ↑ mSS → ↑ HAQ (β=0.003 [0.002–0.004]) 🔹 ↑ mSS → ↓ SF-36 PF (β=−0.10 [−0.15 to −0.05]) 🔹 ↑ # of damaged joints → worse physical function @RheumNow #ACR25 Abstract 1425

Abstrat 1414 Compared to #PsO, early #PsA showed: 🔹 ↑ Dactylitis (66%), Enthesitis (78%), CRP/ESR 🔹 Longer morning stiffness & ↑TJC/SJC 🔹 MRI/US: frequent tenosynovitis & bone changes 🔹 Predictive model combining these features showed Sens 89%, Spec 84% @RheumNow #ACR25

Abstract 0878: In PsA pts w/ lateral epicondyle enthesitis on secukinumab (n=11): 🔹 Improved DAPSA & SPARCC scores 🔹 entheseal tissue biopsy showing shift toward pro-resolving fibroblasts (↑DKK3/CD200⁺) 🔹 ↓ osteoblast-related pathways @RheumNow #ACR25

Kuzkina et al. Efficacy of IL-6i with olokizumab on depression in RA. There appear to be some benefit but anti-depressants still needed. Group 1 is olokizumab alone, other 2 groups have anti-depressants also. @RheumNow #ACR25 Abstr#1323 https://t.co/h2ExYQgKTL

• https://x.com/RichardPAConway/status/1982840462747587012/photo/1